Omnicell, Inc. (NASDAQ: OMCL) Stock Competitors & Peer Comparison

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, GEHCV has a market cap of 25.5B. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while GEHCV trades at $56.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas GEHCV's P/E ratio is N/A. In terms of profitability, OMCL's ROE is +0.03%, compared to GEHCV's ROE of +0.19%. Regarding short-term risk, OMCL is less volatile compared to GEHCV. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check GEHCV's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, BTSG has a market cap of 11.6B. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while BTSG trades at $59.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas BTSG's P/E ratio is 47.69. In terms of profitability, OMCL's ROE is +0.03%, compared to BTSG's ROE of +0.15%. Regarding short-term risk, OMCL is less volatile compared to BTSG. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check BTSG's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, BTSGU has a market cap of 11.5B. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while BTSGU trades at $195.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas BTSGU's P/E ratio is 176.79. In terms of profitability, OMCL's ROE is +0.03%, compared to BTSGU's ROE of +0.15%. Regarding short-term risk, OMCL is more volatile compared to BTSGU. This indicates higher risk in terms of short-term price fluctuations for OMCL.Check BTSGU's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, TEM has a market cap of 11.2B. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while TEM trades at $64.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas TEM's P/E ratio is -128.08. In terms of profitability, OMCL's ROE is +0.03%, compared to TEM's ROE of -0.55%. Regarding short-term risk, OMCL is less volatile compared to TEM. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check TEM's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, SGFY has a market cap of 8.9B. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while SGFY trades at $30.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas SGFY's P/E ratio is 70.91. In terms of profitability, OMCL's ROE is +0.03%, compared to SGFY's ROE of -0.15%. Regarding short-term risk, OMCL is more volatile compared to SGFY. This indicates higher risk in terms of short-term price fluctuations for OMCL.Check SGFY's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, HQY has a market cap of 8.1B. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while HQY trades at $96.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas HQY's P/E ratio is 22.52. In terms of profitability, OMCL's ROE is +0.03%, compared to HQY's ROE of +0.11%. Regarding short-term risk, OMCL is less volatile compared to HQY. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check HQY's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, TXG has a market cap of 7.8B. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while TXG trades at $61.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas TXG's P/E ratio is -104.31. In terms of profitability, OMCL's ROE is +0.03%, compared to TXG's ROE of -0.09%. Regarding short-term risk, OMCL is less volatile compared to TXG. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check TXG's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, HNGE has a market cap of 6.8B. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while HNGE trades at $87.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas HNGE's P/E ratio is 46.70. In terms of profitability, OMCL's ROE is +0.03%, compared to HNGE's ROE of +0.30%. Regarding short-term risk, OMCL is less volatile compared to HNGE. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check HNGE's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, RCM has a market cap of 6B. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while RCM trades at $14.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas RCM's P/E ratio is -102.21. In terms of profitability, OMCL's ROE is +0.03%, compared to RCM's ROE of +0.00%. Regarding short-term risk, OMCL is more volatile compared to RCM. This indicates higher risk in terms of short-term price fluctuations for OMCL.Check RCM's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, WAY has a market cap of 5B. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while WAY trades at $26.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas WAY's P/E ratio is 17.38. In terms of profitability, OMCL's ROE is +0.03%, compared to WAY's ROE of +0.04%. Regarding short-term risk, OMCL is less volatile compared to WAY. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check WAY's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, DOCS has a market cap of 5B. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while DOCS trades at $26.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas DOCS's P/E ratio is 17.47. In terms of profitability, OMCL's ROE is +0.03%, compared to DOCS's ROE of +0.17%. Regarding short-term risk, OMCL is less volatile compared to DOCS. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check DOCS's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, HTFL has a market cap of 4.1B. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while HTFL trades at $47.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas HTFL's P/E ratio is -23.77. In terms of profitability, OMCL's ROE is +0.03%, compared to HTFL's ROE of -0.42%. Regarding short-term risk, OMCL is more volatile compared to HTFL. This indicates higher risk in terms of short-term price fluctuations for OMCL.Check HTFL's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, ONEM has a market cap of 3.4B. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while ONEM trades at $16.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas ONEM's P/E ratio is -7.77. In terms of profitability, OMCL's ROE is +0.03%, compared to ONEM's ROE of -0.24%. Regarding short-term risk, OMCL is less volatile compared to ONEM. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check ONEM's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, PRVA has a market cap of 2.6B. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while PRVA trades at $20.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas PRVA's P/E ratio is 99.00. In terms of profitability, OMCL's ROE is +0.03%, compared to PRVA's ROE of +0.00%. Regarding short-term risk, OMCL is more volatile compared to PRVA. This indicates higher risk in terms of short-term price fluctuations for OMCL.Check PRVA's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, NXGN has a market cap of 1.6B. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while NXGN trades at $23.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas NXGN's P/E ratio is -266.00. In terms of profitability, OMCL's ROE is +0.03%, compared to NXGN's ROE of -0.01%. Regarding short-term risk, OMCL is more volatile compared to NXGN. This indicates higher risk in terms of short-term price fluctuations for OMCL.Check NXGN's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, OMDA has a market cap of 1.4B. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while OMDA trades at $23.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas OMDA's P/E ratio is 338.43. In terms of profitability, OMCL's ROE is +0.03%, compared to OMDA's ROE of +0.02%. Regarding short-term risk, OMCL is less volatile compared to OMDA. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check OMDA's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, AGTI has a market cap of 1.4B. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while AGTI trades at $10.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas AGTI's P/E ratio is -71.79. In terms of profitability, OMCL's ROE is +0.03%, compared to AGTI's ROE of -0.02%. Regarding short-term risk, OMCL is more volatile compared to AGTI. This indicates higher risk in terms of short-term price fluctuations for OMCL.Check AGTI's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, CERT has a market cap of 1.3B. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while CERT trades at $8.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas CERT's P/E ratio is 20.87. In terms of profitability, OMCL's ROE is +0.03%, compared to CERT's ROE of -0.07%. Regarding short-term risk, OMCL is more volatile compared to CERT. This indicates higher risk in terms of short-term price fluctuations for OMCL.Check CERT's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, GDRX has a market cap of 1.2B. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while GDRX trades at $3.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas GDRX's P/E ratio is 11.03. In terms of profitability, OMCL's ROE is +0.03%, compared to GDRX's ROE of +0.03%. Regarding short-term risk, OMCL is less volatile compared to GDRX. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check GDRX's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, TDOC has a market cap of 1.2B. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while TDOC trades at $6.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas TDOC's P/E ratio is -6.57. In terms of profitability, OMCL's ROE is +0.03%, compared to TDOC's ROE of -0.13%. Regarding short-term risk, OMCL is less volatile compared to TDOC. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check TDOC's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, HSTM has a market cap of 858.3M. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while HSTM trades at $29.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas HSTM's P/E ratio is 40.81. In terms of profitability, OMCL's ROE is +0.03%, compared to HSTM's ROE of +0.06%. Regarding short-term risk, OMCL is less volatile compared to HSTM. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check HSTM's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, CCLDO has a market cap of 857.3M. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while CCLDO trades at $27.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas CCLDO's P/E ratio is N/A. In terms of profitability, OMCL's ROE is +0.03%, compared to CCLDO's ROE of +0.17%. Regarding short-term risk, OMCL is more volatile compared to CCLDO. This indicates higher risk in terms of short-term price fluctuations for OMCL.Check CCLDO's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, PHR has a market cap of 750.4M. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while PHR trades at $12.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas PHR's P/E ratio is 43.36. In terms of profitability, OMCL's ROE is +0.03%, compared to PHR's ROE of +0.03%. Regarding short-term risk, OMCL is less volatile compared to PHR. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check PHR's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, SOPH has a market cap of 682.9M. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while SOPH trades at $8.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas SOPH's P/E ratio is -7.33. In terms of profitability, OMCL's ROE is +0.03%, compared to SOPH's ROE of -1.37%. Regarding short-term risk, OMCL is less volatile compared to SOPH. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check SOPH's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, CTEV has a market cap of 669.3M. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while CTEV trades at $39.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas CTEV's P/E ratio is -2.31. In terms of profitability, OMCL's ROE is +0.03%, compared to CTEV's ROE of +1.40%. Regarding short-term risk, OMCL is less volatile compared to CTEV. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check CTEV's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, MPLN-WT has a market cap of 625.2M. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while MPLN-WT trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas MPLN-WT's P/E ratio is N/A. In terms of profitability, OMCL's ROE is +0.03%, compared to MPLN-WT's ROE of +1.40%. Regarding short-term risk, OMCL is less volatile compared to MPLN-WT. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check MPLN-WT's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, ACCD has a market cap of 575.6M. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while ACCD trades at $7.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas ACCD's P/E ratio is -3.08. In terms of profitability, OMCL's ROE is +0.03%, compared to ACCD's ROE of -0.22%. Regarding short-term risk, OMCL is more volatile compared to ACCD. This indicates higher risk in terms of short-term price fluctuations for OMCL.Check ACCD's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, SHCR has a market cap of 531.8M. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while SHCR trades at $1.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas SHCR's P/E ratio is -3.76. In terms of profitability, OMCL's ROE is +0.03%, compared to SHCR's ROE of -0.25%. Regarding short-term risk, OMCL is more volatile compared to SHCR. This indicates higher risk in terms of short-term price fluctuations for OMCL.Check SHCR's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, EVH has a market cap of 518M. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while EVH trades at $4.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas EVH's P/E ratio is 35.42. In terms of profitability, OMCL's ROE is +0.03%, compared to EVH's ROE of -0.99%. Regarding short-term risk, OMCL is less volatile compared to EVH. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check EVH's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, NRC has a market cap of 492.4M. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while NRC trades at $21.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas NRC's P/E ratio is 26.65. In terms of profitability, OMCL's ROE is +0.03%, compared to NRC's ROE of +0.48%. Regarding short-term risk, OMCL is more volatile compared to NRC. This indicates higher risk in terms of short-term price fluctuations for OMCL.Check NRC's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, SLGC has a market cap of 396.2M. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while SLGC trades at $2.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas SLGC's P/E ratio is -3.04. In terms of profitability, OMCL's ROE is +0.03%, compared to SLGC's ROE of -0.19%. Regarding short-term risk, OMCL is less volatile compared to SLGC. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check SLGC's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, SLGCW has a market cap of 396.2M. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while SLGCW trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas SLGCW's P/E ratio is -0.16. In terms of profitability, OMCL's ROE is +0.03%, compared to SLGCW's ROE of -0.19%. Regarding short-term risk, OMCL is less volatile compared to SLGCW. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check SLGCW's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, TBRG has a market cap of 393.6M. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while TBRG trades at $26.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas TBRG's P/E ratio is 9.37. In terms of profitability, OMCL's ROE is +0.03%, compared to TBRG's ROE of +0.02%. Regarding short-term risk, OMCL is more volatile compared to TBRG. This indicates higher risk in terms of short-term price fluctuations for OMCL.Check TBRG's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, MPLN has a market cap of 375M. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while MPLN trades at $23.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas MPLN's P/E ratio is -0.23. In terms of profitability, OMCL's ROE is +0.03%, compared to MPLN's ROE of +1.40%. Regarding short-term risk, OMCL is less volatile compared to MPLN. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check MPLN's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, SY has a market cap of 314.9M. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while SY trades at $2.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas SY's P/E ratio is -7.27. In terms of profitability, OMCL's ROE is +0.03%, compared to SY's ROE of -0.16%. Regarding short-term risk, OMCL is less volatile compared to SY. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check SY's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, TRHC has a market cap of 284M. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while TRHC trades at $10.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas TRHC's P/E ratio is -4.27. In terms of profitability, OMCL's ROE is +0.03%, compared to TRHC's ROE of +121.31%. Regarding short-term risk, OMCL is more volatile compared to TRHC. This indicates higher risk in terms of short-term price fluctuations for OMCL.Check TRHC's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, SMFR has a market cap of 246.4M. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while SMFR trades at $0.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas SMFR's P/E ratio is N/A. In terms of profitability, OMCL's ROE is +0.03%, compared to SMFR's ROE of -0.39%. Regarding short-term risk, OMCL is less volatile compared to SMFR. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check SMFR's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, SPOK has a market cap of 222.4M. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while SPOK trades at $10.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas SPOK's P/E ratio is 17.75. In terms of profitability, OMCL's ROE is +0.03%, compared to SPOK's ROE of +0.09%. Regarding short-term risk, OMCL is less volatile compared to SPOK. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check SPOK's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, AMWL has a market cap of 202.2M. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while AMWL trades at $11.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas AMWL's P/E ratio is -2.69. In terms of profitability, OMCL's ROE is +0.03%, compared to AMWL's ROE of -0.33%. Regarding short-term risk, OMCL is less volatile compared to AMWL. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check AMWL's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, LFMDP has a market cap of 156.9M. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while LFMDP trades at $23.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas LFMDP's P/E ratio is -709.24. In terms of profitability, OMCL's ROE is +0.03%, compared to LFMDP's ROE of -1.79%. Regarding short-term risk, OMCL is more volatile compared to LFMDP. This indicates higher risk in terms of short-term price fluctuations for OMCL.Check LFMDP's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, LFMD has a market cap of 151.9M. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while LFMD trades at $3.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas LFMD's P/E ratio is -6.28. In terms of profitability, OMCL's ROE is +0.03%, compared to LFMD's ROE of -1.79%. Regarding short-term risk, OMCL is less volatile compared to LFMD. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check LFMD's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, OPRX has a market cap of 149.2M. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while OPRX trades at $7.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas OPRX's P/E ratio is 7.29. In terms of profitability, OMCL's ROE is +0.03%, compared to OPRX's ROE of +0.04%. Regarding short-term risk, OMCL is less volatile compared to OPRX. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check OPRX's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, CPSI has a market cap of 133.7M. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while CPSI trades at $9.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas CPSI's P/E ratio is -183.80. In terms of profitability, OMCL's ROE is +0.03%, compared to CPSI's ROE of +0.02%. Regarding short-term risk, OMCL is less volatile compared to CPSI. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check CPSI's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, HCAT has a market cap of 117.5M. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while HCAT trades at $1.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas HCAT's P/E ratio is 7.95. In terms of profitability, OMCL's ROE is +0.03%, compared to HCAT's ROE of -1.30%. Regarding short-term risk, OMCL is less volatile compared to HCAT. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check HCAT's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, AUGX has a market cap of 115.9M. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while AUGX trades at $2.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas AUGX's P/E ratio is -4.99. In terms of profitability, OMCL's ROE is +0.03%, compared to AUGX's ROE of -1.55%. Regarding short-term risk, OMCL is more volatile compared to AUGX. This indicates higher risk in terms of short-term price fluctuations for OMCL.Check AUGX's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, CCLD has a market cap of 105.8M. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while CCLD trades at $2.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas CCLD's P/E ratio is 9.58. In terms of profitability, OMCL's ROE is +0.03%, compared to CCLD's ROE of +0.17%. Regarding short-term risk, OMCL is less volatile compared to CCLD. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check CCLD's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, WORX has a market cap of 88M. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while WORX trades at $5.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas WORX's P/E ratio is -6.40. In terms of profitability, OMCL's ROE is +0.03%, compared to WORX's ROE of -0.35%. Regarding short-term risk, OMCL is less volatile compared to WORX. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check WORX's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, DH has a market cap of 84.7M. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while DH trades at $0.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas DH's P/E ratio is 3.09. In terms of profitability, OMCL's ROE is +0.03%, compared to DH's ROE of -0.79%. Regarding short-term risk, OMCL is less volatile compared to DH. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check DH's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, FORA has a market cap of 67.8M. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while FORA trades at $2.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas FORA's P/E ratio is -24.11. In terms of profitability, OMCL's ROE is +0.03%, compared to FORA's ROE of -0.17%. Regarding short-term risk, OMCL is more volatile compared to FORA. This indicates higher risk in terms of short-term price fluctuations for OMCL.Check FORA's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, CCLDP has a market cap of 59.9M. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while CCLDP trades at $19.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas CCLDP's P/E ratio is N/A. In terms of profitability, OMCL's ROE is +0.03%, compared to CCLDP's ROE of +0.17%. Regarding short-term risk, OMCL is less volatile compared to CCLDP. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check CCLDP's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, SNCE has a market cap of 34.7M. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while SNCE trades at $5.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas SNCE's P/E ratio is -0.27. In terms of profitability, OMCL's ROE is +0.03%, compared to SNCE's ROE of -0.47%. Regarding short-term risk, OMCL is more volatile compared to SNCE. This indicates higher risk in terms of short-term price fluctuations for OMCL.Check SNCE's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, AKLI has a market cap of 34.1M. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while AKLI trades at $0.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas AKLI's P/E ratio is -0.71. In terms of profitability, OMCL's ROE is +0.03%, compared to AKLI's ROE of -0.70%. Regarding short-term risk, OMCL is more volatile compared to AKLI. This indicates higher risk in terms of short-term price fluctuations for OMCL.Check AKLI's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, SHLT has a market cap of 33.6M. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while SHLT trades at $2.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas SHLT's P/E ratio is -3.87. In terms of profitability, OMCL's ROE is +0.03%, compared to SHLT's ROE of -0.50%. Regarding short-term risk, OMCL is more volatile compared to SHLT. This indicates higher risk in terms of short-term price fluctuations for OMCL.Check SHLT's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, ONMD has a market cap of 33M. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while ONMD trades at $0.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas ONMD's P/E ratio is -3.62. In terms of profitability, OMCL's ROE is +0.03%, compared to ONMD's ROE of +2.35%. Regarding short-term risk, OMCL is less volatile compared to ONMD. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check ONMD's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, SHCRW has a market cap of 32.5M. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while SHCRW trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas SHCRW's P/E ratio is -0.00. In terms of profitability, OMCL's ROE is +0.03%, compared to SHCRW's ROE of -0.25%. Regarding short-term risk, OMCL is less volatile compared to SHCRW. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check SHCRW's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, ONMDW has a market cap of 31.1M. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while ONMDW trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas ONMDW's P/E ratio is N/A. In terms of profitability, OMCL's ROE is +0.03%, compared to ONMDW's ROE of +2.35%. Regarding short-term risk, OMCL is less volatile compared to ONMDW. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check ONMDW's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, STRM has a market cap of 23.2M. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while STRM trades at $5.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas STRM's P/E ratio is -2.40. In terms of profitability, OMCL's ROE is +0.03%, compared to STRM's ROE of -0.65%. Regarding short-term risk, OMCL is more volatile compared to STRM. This indicates higher risk in terms of short-term price fluctuations for OMCL.Check STRM's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, RNLX has a market cap of 22.5M. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while RNLX trades at $0.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas RNLX's P/E ratio is -0.33. In terms of profitability, OMCL's ROE is +0.03%, compared to RNLX's ROE of -6.31%. Regarding short-term risk, OMCL is less volatile compared to RNLX. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check RNLX's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, LIFW has a market cap of 22.4M. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while LIFW trades at $3.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas LIFW's P/E ratio is -0.02. In terms of profitability, OMCL's ROE is +0.03%, compared to LIFW's ROE of +1.56%. Regarding short-term risk, OMCL is more volatile compared to LIFW. This indicates higher risk in terms of short-term price fluctuations for OMCL.Check LIFW's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, BBLN has a market cap of 14.1M. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while BBLN trades at $0.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas BBLN's P/E ratio is -0.04. In terms of profitability, OMCL's ROE is +0.03%, compared to BBLN's ROE of +4.89%. Regarding short-term risk, OMCL is less volatile compared to BBLN. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check BBLN's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, BFRG has a market cap of 10.1M. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while BFRG trades at $0.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas BFRG's P/E ratio is -1.18. In terms of profitability, OMCL's ROE is +0.03%, compared to BFRG's ROE of -1.50%. Regarding short-term risk, OMCL is less volatile compared to BFRG. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check BFRG's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, ETAO has a market cap of 9.8M. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while ETAO trades at $1.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas ETAO's P/E ratio is -0.01. In terms of profitability, OMCL's ROE is +0.03%, compared to ETAO's ROE of -13.69%. Regarding short-term risk, OMCL is less volatile compared to ETAO. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check ETAO's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, MGRX has a market cap of 6.8M. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while MGRX trades at $0.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas MGRX's P/E ratio is -0.30. In terms of profitability, OMCL's ROE is +0.03%, compared to MGRX's ROE of -1.06%. Regarding short-term risk, OMCL is less volatile compared to MGRX. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check MGRX's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, UPH-WT has a market cap of 5.3M. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while UPH-WT trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas UPH-WT's P/E ratio is N/A. In terms of profitability, OMCL's ROE is +0.03%, compared to UPH-WT's ROE of -1.05%. Regarding short-term risk, OMCL is less volatile compared to UPH-WT. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check UPH-WT's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, UPH has a market cap of 5.3M. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while UPH trades at $0.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas UPH's P/E ratio is -0.07. In terms of profitability, OMCL's ROE is +0.03%, compared to UPH's ROE of -1.05%. Regarding short-term risk, OMCL is less volatile compared to UPH. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check UPH's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, PEARW has a market cap of 4.1M. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while PEARW trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas PEARW's P/E ratio is -0.00. In terms of profitability, OMCL's ROE is +0.03%, compared to PEARW's ROE of -0.39%. Regarding short-term risk, OMCL is less volatile compared to PEARW. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check PEARW's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, PEAR has a market cap of 4.1M. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while PEAR trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas PEAR's P/E ratio is -0.08. In terms of profitability, OMCL's ROE is +0.03%, compared to PEAR's ROE of -0.39%. Regarding short-term risk, OMCL is less volatile compared to PEAR. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check PEAR's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, OTRK has a market cap of 2.3M. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while OTRK trades at $0.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas OTRK's P/E ratio is -0.02. In terms of profitability, OMCL's ROE is +0.03%, compared to OTRK's ROE of -2.11%. Regarding short-term risk, OMCL is more volatile compared to OTRK. This indicates higher risk in terms of short-term price fluctuations for OMCL.Check OTRK's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, CMAX has a market cap of 1.6M. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while CMAX trades at $0.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas CMAX's P/E ratio is -0.00. In terms of profitability, OMCL's ROE is +0.03%, compared to CMAX's ROE of -2.01%. Regarding short-term risk, OMCL is more volatile compared to CMAX. This indicates higher risk in terms of short-term price fluctuations for OMCL.Check CMAX's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, BFRGW has a market cap of 1.4M. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while BFRGW trades at $0.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas BFRGW's P/E ratio is -0.92. In terms of profitability, OMCL's ROE is +0.03%, compared to BFRGW's ROE of -1.50%. Regarding short-term risk, OMCL is more volatile compared to BFRGW. This indicates higher risk in terms of short-term price fluctuations for OMCL.Check BFRGW's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, ACON has a market cap of 1.3M. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while ACON trades at $2.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas ACON's P/E ratio is -0.27. In terms of profitability, OMCL's ROE is +0.03%, compared to ACON's ROE of -0.59%. Regarding short-term risk, OMCL is less volatile compared to ACON. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check ACON's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, LIFWZ has a market cap of 1.3M. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while LIFWZ trades at $0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas LIFWZ's P/E ratio is N/A. In terms of profitability, OMCL's ROE is +0.03%, compared to LIFWZ's ROE of +1.56%. Regarding short-term risk, OMCL is more volatile compared to LIFWZ. This indicates higher risk in terms of short-term price fluctuations for OMCL.Check LIFWZ's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, HCTI has a market cap of 975.4K. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while HCTI trades at $0.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas HCTI's P/E ratio is -0.11. In terms of profitability, OMCL's ROE is +0.03%, compared to HCTI's ROE of -0.56%. Regarding short-term risk, OMCL is less volatile compared to HCTI. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check HCTI's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, VSEEW has a market cap of 560.3K. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while VSEEW trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas VSEEW's P/E ratio is -0.04. In terms of profitability, OMCL's ROE is +0.03%, compared to VSEEW's ROE of -4.01%. Regarding short-term risk, OMCL is less volatile compared to VSEEW. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check VSEEW's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, MSPRZ has a market cap of 550.4K. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while MSPRZ trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas MSPRZ's P/E ratio is N/A. In terms of profitability, OMCL's ROE is +0.03%, compared to MSPRZ's ROE of +1.56%. Regarding short-term risk, OMCL is less volatile compared to MSPRZ. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check MSPRZ's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, VSEE has a market cap of 245.6K. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while VSEE trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas VSEE's P/E ratio is -0.03. In terms of profitability, OMCL's ROE is +0.03%, compared to VSEE's ROE of -4.01%. Regarding short-term risk, OMCL is less volatile compared to VSEE. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check VSEE's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, KERN has a market cap of 162.3K. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while KERN trades at $0.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas KERN's P/E ratio is -0.01. In terms of profitability, OMCL's ROE is +0.03%, compared to KERN's ROE of -0.20%. Regarding short-term risk, OMCL is less volatile compared to KERN. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check KERN's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, KERNW has a market cap of 162.3K. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while KERNW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas KERNW's P/E ratio is -0.00. In terms of profitability, OMCL's ROE is +0.03%, compared to KERNW's ROE of -0.20%. Regarding short-term risk, OMCL is less volatile compared to KERNW. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check KERNW's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, LIFWW has a market cap of 60.1K. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while LIFWW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas LIFWW's P/E ratio is N/A. In terms of profitability, OMCL's ROE is +0.03%, compared to LIFWW's ROE of +1.56%. Regarding short-term risk, OMCL is more volatile compared to LIFWW. This indicates higher risk in terms of short-term price fluctuations for OMCL.Check LIFWW's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, CMAXW has a market cap of 36.4K. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while CMAXW trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas CMAXW's P/E ratio is N/A. In terms of profitability, OMCL's ROE is +0.03%, compared to CMAXW's ROE of -2.01%. Regarding short-term risk, OMCL is more volatile compared to CMAXW. This indicates higher risk in terms of short-term price fluctuations for OMCL.Check CMAXW's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, ZCMD has a market cap of 32.1K. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while ZCMD trades at $0.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas ZCMD's P/E ratio is -0.03. In terms of profitability, OMCL's ROE is +0.03%, compared to ZCMD's ROE of -0.32%. Regarding short-term risk, OMCL is less volatile compared to ZCMD. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check ZCMD's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, ACONW has a market cap of 13.6K. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while ACONW trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas ACONW's P/E ratio is N/A. In terms of profitability, OMCL's ROE is +0.03%, compared to ACONW's ROE of -0.59%. Regarding short-term risk, OMCL is more volatile compared to ACONW. This indicates higher risk in terms of short-term price fluctuations for OMCL.Check ACONW's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, CHNG has a market cap of 0. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while CHNG trades at $27.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas CHNG's P/E ratio is -152.72. In terms of profitability, OMCL's ROE is +0.03%, compared to CHNG's ROE of -0.05%. Regarding short-term risk, OMCL is more volatile compared to CHNG. This indicates higher risk in terms of short-term price fluctuations for OMCL.Check CHNG's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, NH has a market cap of 0. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while NH trades at $1.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas NH's P/E ratio is -0.12. In terms of profitability, OMCL's ROE is +0.03%, compared to NH's ROE of +0.35%. Regarding short-term risk, OMCL is less volatile compared to NH. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check NH's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, KURIU has a market cap of 0. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while KURIU trades at $9.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas KURIU's P/E ratio is N/A. In terms of profitability, OMCL's ROE is +0.03%, compared to KURIU's ROE of +1.06%. Regarding short-term risk, OMCL is less volatile compared to KURIU. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check KURIU's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, MTBC has a market cap of 0. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while MTBC trades at $3.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas MTBC's P/E ratio is N/A. In terms of profitability, OMCL's ROE is +0.03%, compared to MTBC's ROE of +0.19%. Regarding short-term risk, OMCL is less volatile compared to MTBC. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check MTBC's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, IMS has a market cap of 0. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while IMS trades at $31.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas IMS's P/E ratio is N/A. In terms of profitability, OMCL's ROE is +0.03%, compared to IMS's ROE of +0.27%. Regarding short-term risk, OMCL is less volatile compared to IMS. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check IMS's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, AFFX has a market cap of 0. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while AFFX trades at $14.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas AFFX's P/E ratio is N/A. In terms of profitability, OMCL's ROE is +0.03%, compared to AFFX's ROE of +0.03%. Regarding short-term risk, OMCL is more volatile compared to AFFX. This indicates higher risk in terms of short-term price fluctuations for OMCL.Check AFFX's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, CSLT has a market cap of 0. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while CSLT trades at $2.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas CSLT's P/E ratio is -37.27. In terms of profitability, OMCL's ROE is +0.03%, compared to CSLT's ROE of -0.42%. Regarding short-term risk, OMCL is more volatile compared to CSLT. This indicates higher risk in terms of short-term price fluctuations for OMCL.Check CSLT's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, SMFRW has a market cap of 0. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while SMFRW trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas SMFRW's P/E ratio is N/A. In terms of profitability, OMCL's ROE is +0.03%, compared to SMFRW's ROE of -0.39%. Regarding short-term risk, OMCL is less volatile compared to SMFRW. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check SMFRW's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, MSPRV has a market cap of 0. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while MSPRV trades at $0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas MSPRV's P/E ratio is N/A. In terms of profitability, OMCL's ROE is +0.03%, compared to MSPRV's ROE of N/A. Regarding short-term risk, OMCL is less volatile compared to MSPRV. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check MSPRV's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, NAVA has a market cap of 0. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while NAVA trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas NAVA's P/E ratio is N/A. In terms of profitability, OMCL's ROE is +0.03%, compared to NAVA's ROE of +0.15%. Regarding short-term risk, OMCL is not fully comparable compared to NAVA. This indicates unavailable risk data in terms of short-term price fluctuations for OMCL.Check NAVA's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, CHNGU has a market cap of 0. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while CHNGU trades at $73.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas CHNGU's P/E ratio is N/A. In terms of profitability, OMCL's ROE is +0.03%, compared to CHNGU's ROE of -0.05%. Regarding short-term risk, OMCL is more volatile compared to CHNGU. This indicates higher risk in terms of short-term price fluctuations for OMCL.Check CHNGU's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, CNVY has a market cap of 0. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while CNVY trades at $10.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas CNVY's P/E ratio is -71.50. In terms of profitability, OMCL's ROE is +0.03%, compared to CNVY's ROE of -0.02%. Regarding short-term risk, OMCL is more volatile compared to CNVY. This indicates higher risk in terms of short-term price fluctuations for OMCL.Check CNVY's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, MTBCP has a market cap of 0. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while MTBCP trades at $26.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas MTBCP's P/E ratio is N/A. In terms of profitability, OMCL's ROE is +0.03%, compared to MTBCP's ROE of +0.17%. Regarding short-term risk, OMCL is more volatile compared to MTBCP. This indicates higher risk in terms of short-term price fluctuations for OMCL.Check MTBCP's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, MTBCO has a market cap of 0. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while MTBCO trades at $25.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas MTBCO's P/E ratio is N/A. In terms of profitability, OMCL's ROE is +0.03%, compared to MTBCO's ROE of +0.17%. Regarding short-term risk, OMCL is more volatile compared to MTBCO. This indicates higher risk in terms of short-term price fluctuations for OMCL.Check MTBCO's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.5B. In comparison, CERN has a market cap of 0. Regarding current trading prices, OMCL is priced at $33.08 on the NASDAQ, while CERN trades at $94.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 17.32, whereas CERN's P/E ratio is 55.84. In terms of profitability, OMCL's ROE is +0.03%, compared to CERN's ROE of +0.14%. Regarding short-term risk, OMCL is more volatile compared to CERN. This indicates higher risk in terms of short-term price fluctuations for OMCL.Check CERN's competition here